Lilly Sees Basaglar Sales Begin To Slide
Insulin Glargine Product Sees A Reversal In Q3, Although Nine-Month Sales Still Up
Eli Lilly has seen its Basaglar insulin glargine product suffer a slide in the third quarter of 2020, representing a reversal after a period of growth that has led to a recent plateau. However, nine-month sales were still up on the same period last year.
You may also be interested in...
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.